GenKyoTex Announces Investigator-Initiated Phase 2 Clinical Trial to Evaluate 48-Week Treatment with GKT831 in Patients with Type 1 Diabetes and Kidney Disease

Archamps (France) and Geneva (Switzerland), June 28th, 2017 at 6:00pm CEST.

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that world-renowned diabetes experts Professor Mark Cooper, Head of the Department of Diabetes at Monash University, and Professor Jonathan Shaw, Deputy Director (Clinical and Population Health) at the Baker Heart and Diabetes Institute in Melbourne, Australia, will lead the conduct of a phase 2 clinical trial to evaluate the efficacy and safety of the Company’s lead product candidate, GKT831, in patients with type 1 diabetes and kidney disease (diabetic kidney disease).

Further information on :

https://www.genkyotex.com/images/PDF/GB/1_Press_Releases/2017/20170628_PR_GKTX_JDRF_trial_T1D_Final.pdf